Neo Kuma Ventures' Clara Burtenshaw joins Proactive London's Katie Pilbeam to talks about their psychedelics focused venture capital fund, the first of its kind in Europe.
Burtenshaw discusses their investment thesis, 'we're on a mission to build world class companies that are going to transform the healthcare sector and improve standards of patient care'.
She explains how they invest across three different pillars: Drug discovery and drug development, clinics and delivery services as well as a host of complimentary digital therapeutics, interventions and platforms.'